SG11201808106YA - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation - Google Patents
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulationInfo
- Publication number
- SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA SG 11201808106Y A SG11201808106Y A SG 11201808106YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lateral sclerosis
- amyotrophic lateral
- masitinib
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 September 2017 (28.09.2017) WIPO I PCT (10) International Publication Number WO 2017/162884 Al 111111111111110111011111111111010111110 III 0111111110111H11101111111111111110111111 (51) International Patent Classification: A61K 31/496 (2006.01) A61P 25/28 (2006.01) (21) International Application Number: PCT/EP2017/057134 (22) International Filing Date: 24 March 2017 (24.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16162490.3 25 March 2016 (25.03.2016) EP (71) Applicant: AB SCIENCE [FR/FR]; 3 avenue George V, 75008 Paris (FR). (72) Inventors: MOUSSY, Alain; 22 bis passage Dauphine, 75006 Paris (FR). KINET, Jean-Pierre; 62 Gleason Road, Lexington, Massachusetts 02420 (US). MANSFIELD, Conn; 1 avenue Paul Santy, Batiment C, 69130 Ecully (FR). (74) Agent: ICOSA; 83 avenue Denfert-Rochereau, 75014 Par- is (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) W O 20 17 / 16 288 4 Al (54) Title: USE OF MASITINIB FOR TREATMENT OF AN AMYOTROPHIC LATERAL SCLEROSIS PATIENT SUBPOPU- LATION (57) : The present invention relates to a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, said method comprising administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162490 | 2016-03-25 | ||
| PCT/EP2017/057134 WO2017162884A1 (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808106YA true SG11201808106YA (en) | 2018-10-30 |
Family
ID=55637258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808106YA SG11201808106YA (en) | 2016-03-25 | 2017-03-24 | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10092564B2 (en) |
| EP (1) | EP3240538B1 (en) |
| JP (2) | JP7250312B2 (en) |
| KR (1) | KR102293847B1 (en) |
| CN (1) | CN108883108B (en) |
| AU (1) | AU2017236177B2 (en) |
| BR (1) | BR112018069515A2 (en) |
| CA (1) | CA3018635C (en) |
| DK (1) | DK3240538T3 (en) |
| EA (1) | EA038531B1 (en) |
| ES (1) | ES2899929T3 (en) |
| HU (1) | HUE057398T2 (en) |
| IL (1) | IL261856B (en) |
| MX (1) | MX2018011349A (en) |
| NZ (1) | NZ745778A (en) |
| PL (1) | PL3240538T3 (en) |
| PT (1) | PT3240538T (en) |
| SG (1) | SG11201808106YA (en) |
| SI (1) | SI3240538T1 (en) |
| WO (1) | WO2017162884A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CN110305095A (en) | 2013-10-22 | 2019-10-08 | 综合医院公司 | Cromoglycic acid derivative and the correlation technique of imaging and treatment |
| AU2017321782B2 (en) * | 2016-08-31 | 2022-03-10 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
| JP6663509B2 (en) | 2016-11-25 | 2020-03-11 | ジェヌーヴ インク． | Composition for promoting and protecting differentiation of neural stem cells, and method for inducing nerve regeneration using the same |
| CA3057040A1 (en) * | 2017-03-28 | 2018-10-04 | Novartis Ag | New methods for the treatment of multiple sclerosis |
| BR112019025346A2 (en) * | 2017-05-30 | 2020-06-30 | Deciphera Pharmaceuticals, Inc. | use of 1- [4-bromo-5- [1-ethyl-7- (methylamino) -2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl] -2-fluorophenyl] -3- phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in the platelet-derived growth factor alpha receptor |
| JP7463281B2 (en) * | 2018-03-05 | 2024-04-08 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | Therapies for glaucoma and optic neuropathy by targeting colony stimulating factors - Patent Application 20070229633 |
| EP3817739A4 (en) | 2018-07-02 | 2022-04-13 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and ?-lactose |
| CN112618717A (en) * | 2019-09-24 | 2021-04-09 | 北京大学深圳研究生院 | Use of BTK inhibitors for treating amyotrophic lateral sclerosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| IL166528A0 (en) | 2002-08-02 | 2006-01-15 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MX2009008665A (en) | 2007-02-13 | 2009-08-21 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors. |
| AR080933A1 (en) | 2010-04-20 | 2012-05-16 | Ab Science | TREATMENT OF MULTIPLE SCLEROSIS WITH MASITINIB |
| KR101951220B1 (en) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | Combination als therapy |
| EP2903616B8 (en) * | 2012-10-04 | 2018-02-07 | AB Science | Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer |
| EP3738964A1 (en) | 2013-03-15 | 2020-11-18 | Dana Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| WO2015063318A1 (en) * | 2013-11-04 | 2015-05-07 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
-
2017
- 2017-03-24 EA EA201800499A patent/EA038531B1/en unknown
- 2017-03-24 CN CN201780019760.9A patent/CN108883108B/en active Active
- 2017-03-24 BR BR112018069515A patent/BR112018069515A2/en not_active Application Discontinuation
- 2017-03-24 KR KR1020187026871A patent/KR102293847B1/en active IP Right Grant
- 2017-03-24 JP JP2018549902A patent/JP7250312B2/en active Active
- 2017-03-24 WO PCT/EP2017/057134 patent/WO2017162884A1/en active Application Filing
- 2017-03-24 PT PT177121753T patent/PT3240538T/en unknown
- 2017-03-24 ES ES17712175T patent/ES2899929T3/en active Active
- 2017-03-24 PL PL17712175T patent/PL3240538T3/en unknown
- 2017-03-24 US US15/545,800 patent/US10092564B2/en active Active
- 2017-03-24 SI SI201730997T patent/SI3240538T1/en unknown
- 2017-03-24 CA CA3018635A patent/CA3018635C/en active Active
- 2017-03-24 HU HUE17712175A patent/HUE057398T2/en unknown
- 2017-03-24 NZ NZ745778A patent/NZ745778A/en unknown
- 2017-03-24 MX MX2018011349A patent/MX2018011349A/en unknown
- 2017-03-24 SG SG11201808106YA patent/SG11201808106YA/en unknown
- 2017-03-24 AU AU2017236177A patent/AU2017236177B2/en active Active
- 2017-03-24 DK DK17712175.3T patent/DK3240538T3/en active
- 2017-03-24 EP EP17712175.3A patent/EP3240538B1/en active Active
-
2018
- 2018-09-20 IL IL261856A patent/IL261856B/en unknown
-
2021
- 2021-12-16 JP JP2021204244A patent/JP2022037132A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3240538T3 (en) | 2022-01-31 |
| ES2899929T3 (en) | 2022-03-15 |
| SI3240538T1 (en) | 2022-02-28 |
| CN108883108A (en) | 2018-11-23 |
| IL261856B (en) | 2022-04-01 |
| JP2019515884A (en) | 2019-06-13 |
| KR20180125966A (en) | 2018-11-26 |
| BR112018069515A2 (en) | 2019-04-16 |
| JP2022037132A (en) | 2022-03-08 |
| IL261856A (en) | 2018-10-31 |
| MX2018011349A (en) | 2019-02-07 |
| EA201800499A1 (en) | 2019-03-29 |
| US10092564B2 (en) | 2018-10-09 |
| AU2017236177B2 (en) | 2022-03-31 |
| CN108883108B (en) | 2021-08-06 |
| WO2017162884A1 (en) | 2017-09-28 |
| JP7250312B2 (en) | 2023-04-03 |
| EP3240538A1 (en) | 2017-11-08 |
| PT3240538T (en) | 2021-12-07 |
| KR102293847B1 (en) | 2021-08-26 |
| NZ745778A (en) | 2022-07-01 |
| CA3018635A1 (en) | 2017-09-28 |
| HUE057398T2 (en) | 2022-05-28 |
| US20180117037A1 (en) | 2018-05-03 |
| AU2017236177A1 (en) | 2018-09-20 |
| EA038531B1 (en) | 2021-09-10 |
| DK3240538T3 (en) | 2021-12-06 |
| CA3018635C (en) | 2023-09-26 |
| EP3240538B1 (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805184TA (en) | Combination therapy | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806855WA (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |